Compare · CMRA vs EXEL
CMRA vs EXEL
Side-by-side comparison of Comera Life Sciences Holdings Inc. (CMRA) and Exelixis Inc. (EXEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMRA and EXEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL carries a market cap of $15.77B.
- EXEL has hit the wire 6 times in the past 4 weeks while CMRA has been quiet.
- EXEL has more recent analyst coverage (25 ratings vs 0 for CMRA).
- Company
- Comera Life Sciences Holdings Inc.
- Exelixis Inc.
- Price
- -
- -
- Market cap
- -
- $15.77B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Comera Life Sciences Holdings Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Latest CMRA
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form S-8 POS filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.
- SEC Form POS AM filed by Comera Life Sciences Holdings Inc.
Latest EXEL
- FDA Approval for CABOMETYX issued to EXELIXIS INC
- FDA Approval for COMETRIQ issued to EXELIXIS
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026